Adipotide Research Guide

Full name: Adipotide (FTPP / Prohibitin-Targeting Peptide)

An experimental peptidomimetic designed to trigger targeted fat loss by cutting off the blood supply to white adipose tissue. It remains preclinical and is frequently searched by biohackers alongside other fat-loss peptides, but carries notable safety concerns.

How Adipotide Works

A fusion of a prohibitin-targeting peptide and a pro-apoptotic sequence. It binds prohibitin on the vasculature that feeds white fat, inducing apoptosis of those blood vessels, which starves fat cells and causes them to be resorbed.

Dosing Protocol

• Typical dose: Not established for human use
• Frequency: Research protocols only
• Duration: Short experimental courses
• Route: Subcutaneous injection

Reported Benefits

• Rapid targeted white-fat reduction (animal models)
• Weight loss without appetite suppression
• Reversal of metabolic markers in obese primates

Potential Side Effects

• Kidney toxicity (dose-dependent)
• Dehydration
• Injection site reactions
• Unknown long-term human safety
• No approved human use

Research Citations

1. Adipotide induces weight loss in obese primates (2011) - Produced significant fat loss and improved insulin resistance in obese rhesus monkeys, but with reversible kidney effects.
2. Prohibitin-targeting vascular ablation of fat (2004) - Demonstrated the proof of concept that ablating adipose vasculature causes rapid fat resorption in mice.

Related Weight Management Compounds

• AOD-9604 - Full Profile
• Semaglutide - Full Profile
• Tirzepatide - Full Profile
• Retatrutide - Full Profile
• Tesofensine - Full Profile
• CagriSema - Full Profile

View full Adipotide profile with 3D molecule viewer →